(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 71.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.25%.
Cocrystal Pharma's earnings in 2025 is -$9,671,000.On average, 5 Wall Street analysts forecast COCP's earnings for 2025 to be -$11,482,126, with the lowest COCP earnings forecast at -$11,617,210, and the highest COCP earnings forecast at -$11,433,882. On average, 5 Wall Street analysts forecast COCP's earnings for 2026 to be -$11,622,724, with the lowest COCP earnings forecast at -$13,103,132, and the highest COCP earnings forecast at -$8,828,694.
In 2027, COCP is forecast to generate -$13,637,954 in earnings, with the lowest earnings forecast at -$13,103,132 and the highest earnings forecast at -$14,039,070.